Fantastic football night, all family members are happy 😉 🇩🇪 2 : 🇩🇰 0

🔥 #ESTRO24 was an excellent but packed meeting Missed sessions? The ESTRO Lung Focus Group has released outstanding reports summarising the top lung-related sessions. Don't miss out!

Hot off the press in IJROBP - The Red Journal: the ARREST phase I trial of SABR in poly-metastatic disease, led by Glenn Bauman, MD & Tim Nguyen Average number of lesions = 16 Dose safely escalated to 30 Gy in 5 fractions. sciencedirect.com/science/articl… The phase II/III RCT ARREST2 is underway!

#ESTRO24 presentation on #SBRT for oligometastatic #colorectalcancer highlights its potential to improve survival rates and patients’ quality of life by controlling disease progression and enhancing systemic therapy efficacy. 👉 bit.ly/4f87WKu #radonc Ciro Franzese

THE highlight before summer break Virtual Grand Rounds in Radiation Oncology Prof. Chris Parker presenting and discussing RADICALS-HD trials Tuesday July 16th 17:00 - 17:30 CEST Registration 👇 usz.ch/veranstaltunge…

Do not miss Prof. Chris Parker Chris Parker at tomorrows Virtual Grand Rounds Lecture 👇

Sommerfest Unispital_USZ

📢Exciting Opportunity for Radiation Therapy Professionals! We're thrilled to announce our upcoming blended course on MR-linac Radiotherapy! 👉More information on the programme here: bit.ly/3WmzYta #ESTROSchool24 #radonc

MANY thanks to all centers that allow ESTRO #RadOncs #oligocare community to achieve this great result in Radiotherapy & Oncology! 👉thegreenjournal.com/article/S0167-… Matthias Guckenberger Piet Ost umberto ricardi marta scorsetti Yolanda lievens prof. Barbara Jereczek-Fossa Thomas Zilli Daniela Greto Luca Nicosia MD

Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

🌟 Join us in Lisbon for a course on Image-Guided SBRT! 📍 Lisbon, Portugal For radiation oncologists, physicists & RTTs involved in SBRT & cranial SRS. Learn best practices & team integration strategies to elevate your expertise. 🔗 Register: bit.ly/3Wk5CHC #radonc

Compliance to MDT recs in OMD pts: 👉83.7% of MDT recommendations correctly implemented 👉Reasons for major deviations: physician decision, patient comorbidity or patient decision. 👉Major deviations associated with more than one distant met and worse OS doi.org/10.1016/j.ctro…

Randomized phase II STOP trial of SBRT for oligoprogressive cancer - 127 pts - 3.4% G3 tox, no G4/5 tox - No difference in PFS: median 8.4mo (SBRT) vs 4.3 mo (SoC) - HOWEVER, protocol adherence suboptimal, 35% in SoC treated with SBRT or study withdrawal redjournal.org/article/S0360-…

🛑🛑🛑Here is our STOP RCT looking at SABR in patients with oligoprogressive cancers, just published in @ijrobp www-redjournal-org.proxy1.lib.uwo.ca/article/S0360-… We learned a few important lessons for clinical practice and for the design of future trials...(thread 👇)

ESTRO is calling for experts to represent the Society in EU-funded projects 🇪🇺. If you have expertise in radiation oncology and want to contribute to impactful initiatives in radiation safety, AI, data sharing, and more, apply now: ✅ bit.ly/3z6ST3g

New Comment: Radiation oncology: a call for papers for #ESTRO25 from The Lancet Oncology and Radiotherapy & Oncology #radonc #CancerResearch thelancet.com/journals/lanon…

Still unsure where to submit your TOP research results ? TOP clinical trials ? 👉 #ESTRO25 in Vienna 👉 to be presented in special session featured by The Lancet Oncology and Radiotherapy & Oncology 👉 abstracts to be evaluated for simultaneous publication in these prestigious journals

Call for Papers Green Journal and The Lancet Oncology collaboration For more information, visit: thegreenjournal.com/pb-assets/Heal…

Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial out in European Urology sciencedirect.com/science/articl… The PACE-A trial is a phase 3⃣ randomized study comparing patient-reported outcomes between